Fable Therapeutics CEO Geoff MacKay (L) and co-founder and CTO Philip Kim
October 24, 2024 07:30 AM EDTUpdated 02:33 PM
Financing
AI

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Ryan Cross

Senior Science Correspondent

A fu­sion of this year’s buzzi­est biotech trends — ar­ti­fi­cial in­tel­li­gence and obe­si­ty drugs — is the fo­cus of a new start­up backed with $53.5 mil­lion from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Roche re­turns to Dyno for its AAV tech with $50M up­front

Ex­clu­sive: Moldo­va clears first gene edit­ing study for HBV in hu­mans

Zai Lab un­veils ear­ly lung can­cer da­ta as it looks to chal­lenge Am­gen's Imdell­tra

Al­low­ing No­vo-Catal­ent deal to close would be ‘wrong de­ci­sion’ by an­titrust au­thor­i­ties, Roche CEO says

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times